Vertu Motors
SPECULATIVE BUYVertu, which joined AIM in December with an oversubscribed funding at 60p to play a part in the consolidation of the motor retail sector, has motored in with its second acquisition.
Led by chief executive Robert Forrester, managing director of Reg Vardy before its sale to sector behemoth Pendragon in February 2006, Vertu is buying Blakes for £4.9m in a predominantly cash-based deal. Blakes’ operations include a Vauxhall dealership in Chesterfield and a Vauxhall service centre in Matlock, as well as Peugeot dealerships in Chesterfield and Worksop. These businesses will be re-branded as Bristol Street Motors, in line with Vertu’s first ‘platform’ acquisition, and Forrester sees a strong strategic and geographic fit with the group’s existing operations and brand, and will look to drive growth synergies and margin enhancement from the acquisition.
For the year to December, Blakes scored a small £40,000 pre-tax profit from £59.7m sales, and the deal looks keenly priced, with Blakes’ net asset value estimated at £4.4m following the revaluation of three freehold properties.
Earlier this year, Vertu acquired Bristol Street Motors in a £40m cash and shares transaction (facilitated with the aid of a £26.2m placing) providing the platform for expansion. The profitable Bristol Street sells both new and used cars and also offers commercial vehicle sales and after-sales services – marques offered range from Ford, to Peugeot and Hyundai.
Early days for Vertu on AIM, but with proven management and institutions such as F&C Asset Management and UBS on board, the shares should not be ignored. Speculative buy.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £73m
PE Forecast: n/a
Share price: 80.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
